CORAL GABLES, FL / ACCESSWIRE / August 18, 2017 / As North Korean uncertainty subsides, new concern has risen about the recent attacks in Barcelona. Markets traded lower on Thursday afternoon following the announcement on major media outlets that multiple terror attacks had been carried out in and around the city of Barcelona, Spain. The same market sentiment continues to present itself during pre-market hours Friday morning, however, there are several stocks to watch that are going against the bear trend.
Joey New York, Inc. (JOEY) shares are up over 80% since July 28 and have been as high as $0.87. In the company's most recent announcement, management updated investors on the addition of new, key members of the Joey New York team including high-profile and talented plastic surgeons. Joey New York, Inc. through its wholly-owned subsidiary BotoxLABB offers injectable aesthetic beauty treatments. Botox LABB uses the Allergan portfolio of products which includes Botox, Voluma, Juvederm and Kybella. The LABB also uses the Galderma portfolio of products which includes Restylane, Restylane Silk, Restylane Lyft, Restylane Refyne and Restylane Defyne.
Of note, according to Zion Market Research, the global anti-aging market was valued at USD 140.3 billion in 2015, is expected to reach USD 216.52 billion in 2021 and is anticipated to grow at a CAGR of 7.5% between 2016 and 2021. Furthermore, according to research from Transparency Market Research, the North America facial injectables market is expected to reach a valuation of US$5.8 billion by the end of 2024, nearly tripling in size from where it was just a few years ago. Full Report on (JOEY) Here
Delcath Systems (DCTH) traded higher during pre-market hours on Friday. Since Monday, August 14, shares of the company have moved up over 140% following premarket highs of $0.24. The company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
Delcath recently filed a Definitive Schedule 14A detailing a proposed reverse stock split, subject to shareholder approval. Delcath needs the ability to issue common shares to fund operations, support clinical programs, service the amortization of its Convertible Note and explore alternative equity financing opportunities.
CTI Biopharma (CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. Despite shares being down on Thursday afternoon, Friday morning's pre-market session has seen the stock trading higher by 9% compared to the previous day's closing price. In its most recent announcement, the company stated that its PAC203 Phase 2 Trial of Pacritinib has been initiated.
For free up to the minute financial news updates, text keyword HFNEWS to 474747.
HeraldFinance.com ("HF") is owned by MAD Media Publishing LLC, a Nevada corporation. HF produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. HF has not been compensated: an affiliate company of HR, MIDAM VENTURES LLC, has been compensated $65,000 by JOEY New York ("JOEY"), for a period beginning July 31, 2017 and ending August 31, 2017, to publicly disseminate information about JOEY. We own zero shares.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither HF nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.HeraldFinance.com/.
HF, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect, or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.